Application of SEC-MALS-QELS in the Development of Recombinant Protein-Based Malaria Vaccines

This seminar addresses cutting-edge strategies targeting multiple stages of the Plasmodium parasite lifecycle in mosquitoes and how conjugating poorly immunogenic molecules with potent carriers can revolutionize malaria vaccine development.

Malaria eradication efforts rely on innovative approaches like transmission-blocking vaccines (TBVs)

This study from Dr. David Narum at the NIH, examines human antibodies produced in response to vaccine candidates and how tailored development of vaccines are critical for effectively combating diseases like malaria.